Ozempic vs Wegovy vs Mounjaro vs Zepbound: the four labels in one table
Reviewed 9 sourcesPublished by PepVault
Ozempic, Wegovy, Mounjaro and Zepbound side by side: ingredient, approved use, dose steps, top dose, missed-dose rule and trial weight loss, from each FDA label

- Last reviewed
- Sources
- 9
- Questions
- 7
- Compounds
- 3
The short answer
Ozempic and Wegovy are semaglutide; Mounjaro and Zepbound are tirzepatide, which also acts on the receptor of a second gut hormone, GIP. Ozempic and Mounjaro are approved for type 2 diabetes, Wegovy and Zepbound for weight. All four are weekly shots. In the labels' weight trials, weight fell 14.9% on Wegovy 2.4 mg and 20.9% on Zepbound 15 mg; in SURMOUNT-5, the head-to-head trial, tirzepatide led 20.2% to 13.7%.
Evidence: Approved medicines: every use, dose and trial number here is from the current FDA label (as of November 2026) or a large randomized human trial; the head-to-head SURMOUNT-5 was open-label and maker-funded.

What is the difference between Ozempic, Wegovy, Mounjaro and Zepbound?
Four brand names, two molecules, two makers. Novo Nordisk sells semaglutide as Ozempic and Wegovy; Eli Lilly sells tirzepatide as Mounjaro and Zepbound. Semaglutide copies GLP-1, a hormone the gut releases after a meal: it tells the pancreas to release insulin when blood sugar is high, slows the stomach and quiets appetite. Tirzepatide hits the GLP-1 receptor too, plus the receptor of a second gut hormone, GIP, which is why it is called a dual agonist134.
The table holds each label's facts as of November 2026, with first approvals from Drugs@FDA. Its doses are the label's schedule; the dose a person starts, climbs to and stays on is the prescriber's decision.
| As of November 2026 | Ozempic | Wegovy | Mounjaro | Zepbound |
|---|---|---|---|---|
| Active ingredient | Semaglutide | Semaglutide | Tirzepatide | Tirzepatide |
| Receptors it acts on | GLP-1 | GLP-1 | GIP and GLP-1 | GIP and GLP-1 |
| Maker | Novo Nordisk | Novo Nordisk | Eli Lilly | Eli Lilly |
| Approved for | Blood sugar in type 2 diabetes; in type 2 diabetes, heart risk with heart disease and kidney risk with kidney disease | Weight loss and keeping it off; heart risk in heart disease with obesity or overweight; the liver disease MASH (shot only) | Blood sugar in type 2 diabetes; heart risk in type 2 diabetes at high risk | Weight loss and keeping it off; obstructive sleep apnea with obesity |
| Ages | Adults | Adults; the shot also from age 12 with obesity | Adults, and from age 10 for blood sugar | Adults |
| First FDA approval | Dec 5, 20179 | Jun 4, 2021; tablets Dec 22, 20259 | May 13, 20229 | Nov 8, 20239 |
| Forms | Multi-dose pen, prefilled syringe; Ozempic tablets on a shared label with Rybelsus2 | Single-dose pen or syringe, FlexTouch pen; tablets | Single-dose pen or vial, multi-dose vial, KwikPen | Single-dose pen or vial, multi-dose vial, KwikPen |
| How often | Shot weekly; tablet daily | Shot weekly; tablet daily | Weekly | Weekly |
| The shot's dose steps | 0.25 mg for 4 weeks, then 0.5 mg; 1 mg, then 2 mg, each after at least 4 weeks, if blood sugar needs it | 0.25, 0.5, 1 and 1.7 mg, 4 weeks each; 2.4 mg from week 17 | 2.5 mg to start; up 2.5 mg after at least 4 weeks, only if blood sugar needs it | 2.5 mg for 4 weeks, then 5 mg; up 2.5 mg after at least 4 weeks |
| Dose to stay on | 0.5, 1 or 2 mg | 2.4 mg (recommended) or 1.7 mg | The step that controls blood sugar | 5, 10 or 15 mg; 10 or 15 mg for sleep apnea |
| Top dose of the shot | 2 mg | 7.2 mg (Wegovy HD), adults | 15 mg; 10 mg in children | 15 mg |
| Missed shot | Take it within 5 days; later, skip it | Take it if the next dose is more than 2 days away; else skip it | Take it within 4 days; later, skip it | Take it within 4 days; later, skip it |
| Half-life | About 1 week | About 1 week | About 5 days | About 5 to 6 days |
| Label read | Version 20, revised June 20261 | Version 19, revised June 20263 | Version 40, revised August 20264 | Version 40, revised August 20265 |
Type the brand on your prescription into PepVault, Ozempic, Wegovy, Mounjaro or Zepbound, and it finds the ingredient and sets the shot up as a weekly pen dosed in mg, ready for your reminders. Set reminders in PepVault
Half-life is the time the body takes to clear half of a dose; the Mounjaro label credits tirzepatide's five days for once-weekly dosing14.

Are Ozempic and Wegovy the same drug?
Same molecule, two labels. Both shots start at 0.25 mg a week and reach 0.5 mg after four weeks13. Then they part: Ozempic is dosed to blood sugar and tops out at 2 mg; Wegovy is dosed to weight, to 2.4 mg from week 17 and, for adults who tolerate 2.4 mg for at least four weeks, up to 7.2 mg, sold as Wegovy HD3. Each step is in the Wegovy and Ozempic dosage guide.
Both now come as a daily tablet too. Ozempic tablets (1.5, 4 and 9 mg) share one label with Rybelsus and are approved for type 2 diabetes2. Wegovy tablets climb over three months to 25 mg a day and are approved for weight and heart risk in adults3. The Wegovy label advises against combining it with any other semaglutide or GLP-1 medicine, so the two brands are not taken together3.
Are Mounjaro and Zepbound the same drug?
Yes: the same tirzepatide, the same six strengths from 2.5 to 15 mg and the same four ways to get it, a single-dose pen, a single-dose vial, a four-dose vial and a four-dose KwikPen45. The difference is the job. Mounjaro's label raises the dose only if blood sugar needs more help, and it is approved for children with type 2 diabetes from age 104. Zepbound's label climbs on a plan to a dose of 5, 10 or 15 mg; 2.5 mg is a start only5. The tirzepatide dosage guide walks every step.
Zepbound is also the only one of the four approved for moderate to severe obstructive sleep apnea, where the airway keeps closing during sleep, in adults with obesity5. Its label advises against combining it with Mounjaro or any GLP-1 medicine5.
Which one causes the most weight loss?
Tirzepatide, in both large phase 3 trials that tested it head to head against semaglutide, one for weight and one for diabetes. Each weight label reports the average change from the starting weight, counting everyone randomized, including people who stopped the drug. Every trial in the table added a lower-calorie diet and activity counseling to the drug or to a placebo, a dummy shot35.
| Trial | Drug and weekly dose | Weeks | Average weight change | Placebo | Lost 20% or more |
|---|---|---|---|---|---|
| STEP 1 | Wegovy shot 2.4 mg | 68 | −14.9% | −2.4% | 30.2% (placebo 1.7%)36 |
| STEP UP | Wegovy shot 2.4 mg / 7.2 mg | 72 | −15.5% / −18.8% | −3.9% | 32.3% / 45.5% (placebo 2.8%)3 |
| OASIS 4 | Wegovy tablet 25 mg a day | 64 | −13.6% | −2.4% | 27.9% (placebo 3.1%)3 |
| SURMOUNT-1 | Zepbound 5 / 10 / 15 mg | 72 | −15.0% / −19.5% / −20.9% | −3.1% | 30.0% / 50.1% / 56.7% (placebo 3.1%)57 |
The rows enrolled different people, so they are not a race. SURMOUNT-5 is the race: 751 adults with obesity and no diabetes were randomly given tirzepatide (10 or 15 mg) or semaglutide (1.7 or 2.4 mg), each at the highest dose they tolerated, for 72 weeks. Weight fell 20.2% on tirzepatide and 13.7% on semaglutide, and waists shrank 18.4 cm against 13.0 cm8. It was open-label, so everyone knew their drug, and Eli Lilly, tirzepatide's maker, funded it8. It stopped semaglutide at 2.4 mg, below the 7.2 mg Wegovy's label now allows.
PepVault's weight log keeps every weigh-in on one chart, so your own curve is there to read beside these averages. Track your weight in PepVault
Do Ozempic and Mounjaro cause weight loss too?
They do, though neither is approved for it. Their labels report the diabetes trials' weight in kilograms, and people with diabetes tend to lose less: on Wegovy 2.4 mg, 9.6% in adults with type 2 diabetes against 14.9% without3. The Mounjaro label also carries SURPASS-2, the open-label head-to-head trial in which 1,879 adults on metformin added tirzepatide or semaglutide 1 mg, Ozempic's middle dose4.
| Trial | Drug and weekly dose | Weeks | Weight change | Compared with |
|---|---|---|---|---|
| SUSTAIN 1 | Ozempic 0.5 / 1 mg | 30 | −3.8 / −4.7 kg (8.4 / 10.4 lb) | Placebo −1.2 kg1 |
| SURPASS-1 | Mounjaro 5 / 10 / 15 mg | 40 | −6.3 / −7.0 / −7.8 kg (13.9 / 15.4 / 17.2 lb) | Placebo −1.0 kg4 |
| SURPASS-2 | Mounjaro 5 / 10 / 15 mg | 40 | −7.6 / −9.3 / −11.2 kg (16.8 / 20.5 / 24.7 lb) | Semaglutide 1 mg −5.7 kg (12.6 lb)4 |
In SURPASS-2, HbA1c, the blood test of average blood sugar over about three months, fell 2.0, 2.2 and 2.3 points on the three Mounjaro doses against 1.9 on semaglutide 1 mg; every Mounjaro dose beat it4. Ozempic's 2 mg dose was not in that trial.
Do the side effects differ between the four?
The kind is the same: the stomach. Nausea, diarrhea, vomiting and constipation lead every label's list, and the Ozempic, Mounjaro and Zepbound labels say they came mostly while the dose was being raised145. Nausea in each label's main trials, against placebo: Ozempic 15.8% at 0.5 mg and 20.3% at 1 mg (6.1%); Wegovy 44% at 2.4 mg (16%); Mounjaro 12%, 15% and 18% at 5, 10 and 15 mg (4%); Zepbound 25%, 29% and 28% (8%)1345. Different trials, so not a ranking. One effect is the top Wegovy dose's own: tingling, burning or sensitive skin in 22% on 7.2 mg, against 6% on 2.4 mg and 0.3% on placebo3. In the weight trials, side effects made 6.8% stop Wegovy 2.4 mg and 4.8% to 6.7% stop Zepbound, against 3.2% and 3.4% on placebo35.
All four labels carry the same boxed warning: the drug caused thyroid C-cell tumors in rodents, whether it does in people is unknown, and anyone with a personal or family history of medullary thyroid cancer or the syndrome MEN 2 should not use it1345.
Commonly reported: food noise, the steady background thinking about food, going quiet within the first weeks; on tirzepatide, meals ending early, with nausea or tiredness for a day or two after the shot, mostly after a dose increase.
When to get help Severe stomach pain that does not go away, with or without vomiting and sometimes reaching the back, is the one the labels say to stop for and call a doctor about right away35.
Where do I compare two of them in detail?
Each pair people search has its own page built from the same labels, and each brand a full page with storage and side effects.
- Same ingredient: Ozempic vs Wegovy; Mounjaro vs Zepbound.
- Diabetes brands: Ozempic vs Mounjaro.
- Weight brands: Wegovy vs Zepbound.
- Across the line: Ozempic vs Zepbound; Wegovy vs Mounjaro.
- Next door: Ozempic vs Rybelsus; Wegovy vs Foundayo.
- The four brand pages, and the drugs hub with every brand.
Whichever brand you are on, PepVault logs each weekly shot with its dose and site, so every step of the climb is on record for your next appointment. Log it in PepVault
Sources
- Ozempic (semaglutide) injection, prescribing information. Novo Nordisk. DailyMed, set adec4fd2-6858-4c99-91d4-531f5f2a2d79, version 20, revised June 2026. dailymed.nlm.nih.gov
- Rybelsus and Ozempic (semaglutide) tablets, prescribing information. Novo Nordisk. DailyMed, set 27f15fac-7d98-4114-a2ec-92494a91da98, version 14, revised January 2026. dailymed.nlm.nih.gov
- Wegovy (semaglutide) injection and tablets, prescribing information. Novo Nordisk. DailyMed, set ee06186f-2aa3-4990-a760-757579d8f77b, version 19, revised June 2026. dailymed.nlm.nih.gov
- Mounjaro (tirzepatide) injection, prescribing information. Eli Lilly. DailyMed, set d2d7da5d-ad07-4228-955f-cf7e355c8cc0, version 40, revised August 2026. dailymed.nlm.nih.gov
- Zepbound (tirzepatide) injection, prescribing information. Eli Lilly. DailyMed, set 487cd7e7-434c-4925-99fa-aa80b1cc776b, version 40, revised August 2026. dailymed.nlm.nih.gov
- Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity (STEP 1). N Engl J Med. 2021;384:989-1002. PubMed 33567185
- Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity (SURMOUNT-1). N Engl J Med. 2022;387:205-216. PubMed 35658024
- Aronne LJ et al. Tirzepatide as compared with semaglutide for the treatment of obesity (SURMOUNT-5). N Engl J Med. 2025;393:26-36. PubMed 40353578
- U.S. Food and Drug Administration. Drugs@FDA: NDA 209637 (Ozempic), NDA 215256 and NDA 218316 (Wegovy injection and tablets), NDA 215866 (Mounjaro), NDA 217806 (Zepbound), original approval dates. accessdata.fda.gov
Newsletter · Weekly
The weekly peptide briefing.
New guides, the week’s peptide news, one tool. Free, one email a week, unsubscribe anytime.